Objectives: This work was carried out to construct a novel liposomal azithromycin formulation and examine its antimicrobial effects against Pseudomonas aeruginosa.
Introduction
Cystic fibrosis (CF) is a life-threatening autosomal recessive hereditary disorder, which usually affects Caucasian populations in the ratio of one among 2000 newborns. 1 -3 It is also considered to be a multifunctional or multisystemic disease, as it affects several organs and systems of the body, such as liver, pancreas, gastrointestinal tract, reproductive system and lungs in particular. 4, 5 Among these organs, pulmonary injury is mainly responsible for patient death in the CF population. 6 Recurrent pulmonary infection and inflammation are the major risk factors associated with the disease. 7 CF is caused by the mutations in the CF transmembrane conductance (CFTR) gene. 8 Approximately 2000 CFTR mutations have been identified that can be classified into six types based on their effect. 9 The deletion of phenylalanine in the amino acid position at D508 is the most common mutation, and is responsible for the majority of CF cases. 10 The normal function of CFTR in lungs is to regulate the water and salts across the epithelial cells, whereas in abnormal or dysfunctional CFTR in the lungs there is hyperabsorption of sodium from the epithelial surface, which results in the depletion of airway surface liquid. 11 These changes in airway surface depletion lead to the prevention of normal ciliary beating and accumulation of thick and sticky mucus on the airway surface, which leads to favourable conditions for microbial colonization. 12 The major opportunistic pathogens implicated in pulmonary infection are Gram-positive Staphylococci species and Gram-negative Pseudomonas aeruginosa and Burkholderia cenocepacia. 13 Toxic shock syndrome toxin-1, coagulases and proteases are virulence factors produced by the Staphylococci species.
14 P. aeruginosa releases a large number of virulence factors, including lipase, chitinase, elastase, protease, exotoxin A, neuraminidase, catalase and superoxide dismutase. 15, 16 Siderophores, lipases and proteases are virulence factors released by B. cepacia. 17 Among all bacteria, the most opportunistic human pathogen is P. aeruginosa, which is mainly responsible for pulmonary exacerbation in the CF population. 18, 19 It is a Gram-negative bacillus that mainly affects the lower respiratory tract of the lungs, and is a ubiquitous organism mainly found on the surface of plants and in water, soil and hospitals. 20 It is the most prevalent respiratory bacterial pathogen that affects CF individuals with compromised immune systems. 21 Nowadays it is called a 'superbug' because of P. aeruginosa-engendered resistance. 22 P. aeruginosa exhibits different resistance mechanisms such as decreasing antibiotic permeability and increasing active efflux of the antibiotic across the bacterial cell surface. 23, 24 It uses a mechanism called quorum sensing (QS), which is cell-cell communication of signalling molecules produced in response to bacterial density. 25 QS signalling molecules regulate the gene expression that controls the formation of biofilms and the production of different virulence factors, thereby contributing to P. aeruginosa's tolerance to antimicrobial chemotherapy. 26, 27 Virulence factors such as lipase, chitinase, elastase and proteases released from P. aeruginosa can cause tissue damage and proteolysis imbalance and are thought to be a leading cause of immunomodulation. 28, 29 Biofilm formation is one of the major systems by which bacteria bypass chemotherapy. 30 Biofilms are a group of organisms that grow attached to a surface and are embedded in an extracellular matrix composed of proteins and exopolysaccharides. 26 P. aeruginosa biofilms can cause chronic infections due to increased tolerance to antibiotics and resistance to phagocytosis, as well as components of the immune system, innate as well as adaptive, resulting in immune complex-mediated chronic inflammation. 30 Antibiotics such as macrolides are widely used in the treatment of pseudomonal lung infections. 31 -33 Macrolides are a group of compounds that have a large lactone ring in their structure. 23 The drug of choice among macrolides is azithromycin, a secondgeneration, broad-spectrum antibiotic usually used in the treatment of lower respiratory tract infections. 34, 35 Azithromycin accumulates effectively in the phagocytes, thereby increases antibiotic concentration at infection sites. 36 Azithromycin acts by binding to the 50S subunit of the bacterial ribosome, thus inhibiting bacterial protein synthesis. Azithromycin can be used as a cell-to-cell blocking agent affecting the formation of biofilms in P. aeruginosa. 37 In lung diseases such as CF it has been proven that azithromycin shows improved clinical outcomes in patients with extended usage. 38 In contrast, a study demonstrated that the typical use of azithromycin is not effective against P. aeruginosa infections because of bacterial outer-membrane impermeability and efflux pump. 33 The main mechanism of macrolide resistance in P. aeruginosa biofilms is due to hyperexpression of the MexCD-OprJ efflux pump, which plays an important role in antibiotic resistance. 39 The MexCD-OprJ efflux pump is mainly expressed due to mutations in the gene nfxb that result in an increase in efflux genes and encode a repressor of MexCD-OprJ efflux pump expression. 40 -42 Higher doses of azithromycin also resulted in increased serum levels and hepatotoxicity due to failure of the catalytic ability of cytochrome CYP3A4. 43 It has been reported that 40 different hydrolytic enzymes, including proteases, nucleases, glycosidases, lipases, phospholipases, phosphatases, sulfatases and many proteins of yet unknown function, have been identified as comprising lysosomal content; 44 among them phospholipase A 1 is majorly responsible for drug-induced phospholipidosis by azithromycin. 45 In addition, the accumulation of azithromycin in lysosomes may hinder phospholipase A 1 activity, resulting in storage disorder phospholipidosis, indicating excess accumulation of phospholipids in the tissues, which causes inflammatory reactions and histopathological alterations in organs. 38,46 -48 To overcome these problems of P. aeruginosa's resistance to azithromycin, and the drug's toxic effects and its atypical pharmacokinetics, 43 new drug-delivery systems like liposomes have been developed. Liposomes are considered to be safe, reliable and biodegradable drug-delivery systems as they are mainly made up of phospholipids and their derivatives, which could increase the efficacy and reduce the toxicity associated with drugs. 49 -51 They are small, round lipid vesicles with sizes varying from the nanometer to micrometer range. 52 A liposome consists of one or more lipid bilayers surrounded by an aqueous core. 53 It also has a hydrophilic head and hydrophobic tail along with the lipid bilayers. 54 Usually hydrophilic drugs are incorporated into the aqueous core and lipophilic drugs into the bilayers of the phospholipid. 55, 56 The use of liposomes has been shown to increase drug concentration at the site of infection and reduce toxic effects. 50, 57 Previous work done by our group showed that erythromycin could be encapsulated with greater efficacy and stability. 58 Furthermore, Alhajlan et al. 59 showed that clarithromycin-loaded liposomes exhibited an increase in antibacterial effects against P. aeruginosa and a decreased toxic effect on human lung cells. Oh et al. 60 revealed that liposome-encapsulated azithromycin or ciprofloxacin focus on the reticuloendothelial system, which in turn provides efficient direct delivery of antibiotics into the infected cells, resulting in a more effective treatment for Mycobacterium avium infections.
In the current work we developed, characterized and evaluated a novel liposomal azithromycin formulation for its antimicrobial effects against P. aeruginosa. Liposomal azithromycin activity against biofilm-forming P. aeruginosa was assessed and the effect of a subinhibitory concentration of free and liposomal azithromycin was studied on P. aeruginosa QS, virulence factors and bacterial motility. In addition, the liposome and bacterial interactions were investigated. Furthermore, the toxicities of the liposomal formulation on erythrocytes and cultured A549 lung cells were evaluated in vitro.
Materials and methods

Chemicals and media
Azithromycin was obtained from Bonn Schtering Bio Sciences (Pondicherry, India). 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Cholesterol, Triton X-100, PKH2-GL kit, trypan blue, elastin-Congo red, chitin azure, b-D-galactopyranoside, RPMI (Roswell Park Memorial Institute medium), Dulbecco's PBS and agarose were purchased from Sigma-Aldrich (Oakville, Ontario, Canada). Tryptic soy agar, tryptic soy broth, LB broth and LB agar were obtained from Becton Dickinson Microbiology Systems (Oakville, Ontario, Canada). The cell viability assay kit was purchased from Fisher Scientific (Ottawa, Ontario, Canada). CAMHB for culturing microorganisms was purchased from Becton Dickinson (Franklin Lakes, NJ, USA).
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Cell culture
A549 human lung carcinoma epithelial cells were obtained from the ATCC (CCL-185, Manassas, VA, USA) and cultured in DMEM supplemented with 10% heat-inactivated FBS; this toxicity study was performed without the addition of antibiotics. The cells were grown to 85% confluence in 5% CO 2 at 378C and maintained using traditional cell culture techniques. 61 
Bacterial strains
Bacillus subtilis (ATCC 6633) laboratory strain was used as an indicator for testing azithromycin activity. P. aeruginosa strain (PAO1) was generously donated by Dr R. E. W. Hancock (University of British Columbia) and clinical isolates of P. aeruginosa (PA-1, PA-5, PA-3, PA-7, PA-M13640, PA-M13641-1, PA-M13641-2, PA-48912-1 and PA-48912-2) were purchased from PML Microbiologicals (Mississauga, Ontario, Canada), with some being obtained from the Memorial Hospital's Clinical Microbiology Laboratory (Sudbury, Ontario, Canada). All the bacterial strains were stored at 2808C in CAMHB supplemented with 10% glycerol. All strains were grown for 18 h in CAMHB prior to the MIC, MBC, QS and virulence factor experiments. For the acyl homoserine lactones (AHL) detection Agrobacterium tumefaciens strain A136 (pCF218)(pCF372) (Ti-) was used as the biosensor and cultured in LB broth at 308C.
Preparation of liposomes
The dehydration -rehydration vesicle (DRV) method was used for the preparation of liposomes. DPPC and cholesterol in a molar ratio of 6:1 (lipid to cholesterol) were used. DPPC (0.11382 g) and cholesterol (0.01 g) were added to a round-bottomed flask and then dissolved in a sufficient amount of chloroform-methanol (2: 1) mixture. The mixture in the roundbottomed flask was dried to a lipid film with a rotary evaporator (Rotavapor; Bü chi Labortechnik AG) in a water bath at 418C under controlled vacuum (V-800, Brinkman). A 0.03 g aliquot of azithromycin dissolved in PBS (pH 7.4) was added to rehydrate the lipid film. The lipid suspensions in PBS were vortexed for 5 min and then sonicated for 2 min (cycles of 45 s on and 10 s off) in an ultrasonic dismembrator bath (FS20H; Fisher Scientific, Ottawa, Ontario, Canada) with amplitude of 45 Hz (Model 500, Fisher Scientific). The lipid suspension was divided into aliquots of 1 mL. The tubes were frozen for 15 min then freeze dried in a freeze-dried system (model 77540, Labanco Corporation, Kansas City, MO, USA). The obtained powdered formulations were stored in a freezer at 08C until use. For rehydration, 100 mL of PBS was added and the mixture was vortexed and incubated for 5 min at 408C. This step was repeated three times and finally 700 mL of PBS was added to make it up to 1000 mL of suspension. The excess of unencapsulated drug was removed following three rounds of washing with PBS using a centrifuge (16 000 g for 15 min at 48C).
Microbiological assay for the measurement of azithromycin
To measure the encapsulation efficiency of azithromycin into liposomal vesicles, laboratory-strain B. subtilis (ATCC 6633) was used as an indicator organism as suggested by the CLSI. Agar diffusion assay was used to quantify the concentrations of azithromycin incorporated into liposomes. 61 B. subtilis (ATCC 6633) was cultured overnight in CAMHB, and a bacterial solution was prepared equivalent to 0.5 McFarland standards (1.5×l0 8 cfu/mL). The bacterial cells were then added to an autoclaved molten agar solution at 418C and immediately discharged into a sterile glass plate (440×340 mm) to form a thin layer of agar and bacteria. The liposomal azithromycin sample was centrifuged at 12 000 g for 20 min at 48C and Triton X-100 in PBS (0.2%, v/v) was added to the obtained pellet in order to release the drug from the liposome. 62 We must point out that this concentration of Triton X-100 (0.2%) has no effect on the bacterial growth. A well-puncher device was used to make wells of 5 mm in diameter, which were filled with 25 mL of liposome samples or standard solutions of azithromycin, and the glass plate was incubated for 18 h at 378C. 63, 64 After the incubation period of 18 h, inhibition zones obtained on the plate were measured in triplicate. In order to quantify the encapsulation efficiency of the liposomal azithromycin formulations, average values of the triplicates were used. The sensitivity of the microbiological assay was 0.00390 mg/L and the quantifiable limit for azithromycin was 0.003 mg/L. For azithromycin, the standard curve linearity extended over the range 0.003 -2 mg/L and gave a correlation coefficient .0.99. The concentrations of the obtained measurements are the means of at least three independent experiments measured in triplicate for each experiment.
Determination of encapsulation efficiency
The encapsulation efficiency of liposomal azithromycin was determined as the percentage of azithromycin entrapped in the liposomes (determined by microbiological assay as mentioned in the previous paragraph) with respect to the initial amount of the azithromycin in solution. 65 The encapsulation efficiency was measured using the formula:
where C DRVs corresponds to the concentration of the antibiotic entrapped in DRVs and C sol corresponds to the initial concentration of the antibiotic added to the mixture. The concentration of the entrapped azithromycin in the liposome was determined by the microbiological assay as described above.
Determination of particle size and polydispersity index
The mean diameter of liposomes and the polydispersity index were measured using a submicron particle sizer model 270 (Nicomp, Santa Barbara, CA, USA). 63, 66 The liposomal azithromycin samples obtained after rehydration by adding 1000 mL of PBS were subjected to particle size analysis. Liposomal azithromycin was diluted in clear glass tubes with doubledistilled water to get a sufficient reading in the range 250 -350 kHz for the photo pulse to obtain the particle size data. The process was repeated two or three times with the liposomal azithromycin sample to take an average value of the particle size.
Differential scanning calorimetry (DSC) characterization
DSC analysis was performed using the TA Instruments Q100 differential scanning calorimeter (Grimsby, Ontario, Canada). A scan rate of 108C/min was employed with a temperature range of 25 -2008C. An 5 -7 mg sample was used for analysis, using an empty pan as reference. Pure DPPC, physical mixture-1 (DPPC, cholesterol), physical mixture-2 (DPPC, cholesterol and azithromycin) and azithromycin-loaded liposome samples were prepared for thermal analysis. 67 The measurements of each sample were repeated three times. The main phase transition temperatures were determined using TA universal analysis 2000 program.
Stability studies of liposomal azithromycin
The stability study of liposomal azithromycin was evaluated in PBS at 4 and 378C. The stability of liposomal azithromycin was measured as the percentage retention of the initial encapsulated azithromycin after the incubation period of time at 4 and 378C. 65 Briefly, liposomal azithromycin was suspended in PBS and incubated in a water bath shaker with mild agitation at 100 rpm (Julabo SW22 Incubator Shaker; Labortechnik, Seelbach, Solleti et al.
Germany). After incubation times of 0, 2, 4, 6, 8, 24 and 48 h, samples were centrifuged at 18000 g for 15 min at 48C to remove the released drug. 65, 68 The supernatants of the liposomal azithromycin samples were collected, and 25 mL was transferred into puncher-made holes on a plate containing agar prepared with B. subtilis ATCC 6633. The plates were then incubated at 378C for 18 h, and the inhibition zones were measured.
Determination of the MICs and MBCs
MICs were determined for clinical strains of mucoid and non-mucoid P. aeruginosa (PA-1, PA-5, PA-3, PA-7, PA-M13640, PA-M13641-1, PA-M13641-2, PA-48912-1 and PA-48912-2) by the microbroth dilution technique. The bacterial strains were subjected to 0.5 McFarland standards and transferred to 96-well plates as reported previously. 61 The bacterial strains were exposed to different dilutions of azithromycin in the plate. The plates were incubated for 24 h at 378C. 69 After incubation MIC results were noted by visually observing the point at which a particular concentration of drug inhibited the growth of organisms. The selected concentrations were subjected to MBC method by inoculating the sample to the agar plates and incubating for 24 h at 378C to evaluate the growth of bacteria on the plates. 70 The results were taken from three separate experiments.
Effect of subinhibitory concentrations of free and liposomal azithromycin on the growth of P. aeruginosa A culture of P. aeruginosa was used for preparing a bacterial solution equivalent to 0.5 McFarland (1.5×l0 8 bacteria/mL) or OD 600 ¼ 0.13 medium. Then, the medium was left in an incubator shaker for 1 h at 378C, 250 rpm to double the bacterial number to OD 600 ¼0.26 as reported previously. 71 An equal volume of the antibiotic at 1 MIC, 1/2 MIC, 1/4 MIC and 1/8 MIC and then 25 mL of medium were added to the fifth flask (control). A 25 mL aliquot of the doubled bacteria was added to all flasks to obtain a total volume of 50 mL of solution in each flask. Flasks were then incubated at 378C at 250 rpm. Bacteria cell density was measured spectrophotometrically at 600 nm every 1 h for 8 h, and then growth was measured again at 24 h. The results were taken from three separate experiments.
Determining antibacterial activity of liposomal azithromycin against PAO1 by minimum biofilm eradication concentration (MBEC) assay P. aeruginosa PAO1 strain was adjusted to 0.5 McFarland standards (1.5×l0 8 cfu/mL), transferred to an MBEC TM (CBD-Innovotech, AB, Canada) plate and incubated at 378C for 72 -96 h. Every 24 h, the broth in the plate was replaced to remove the unattached bacteria from lid pegs, and the plates with pegs were washed with PBS using another 96-well plate. After 96 h biofilms were harvested from the pegs using sterile pliers and suspended in tubes of 900 mL PBS. Six cycles of sonication were applied to detach bacteria from the pegs. Each cycle was for 10 s followed by vortexing the tubes. The bacteria were then treated with different concentrations of free azithromycin and liposomal azithromycin for 24 h at 378C. The samples of bacteria untreated with drugs were considered as controls. The tubes containing peg lids with PBS were subjected to 10-fold serial dilution to reduce the concentration, and 100 mL of each sample was plated on CAMH agar plates for 24 h at 378C for the determination of cfu.
b-Galactosidase activity assay
The AHL production levels from P. aeruginosa exposed to free and liposomal azithromycin at subinhibitory concentrations were tested by measuring the ability of P. aeruginosa AHL signalling molecules released into the supernatants to activate the production of b-galactosidase in the reporter strain A. tumefaciens (A136). 72 Briefly, bioassay tubes containing 4 mL of reporter strain and 1 mL of supernatant were incubated at 308C in a water bath for a period of 5 h with rotation at 100 rpm followed by measurement of the bacterial cell density (as the OD 600 ) prior to centrifugation. The supernatants were eliminated, and the pellets were suspended in an equal volume of Z buffer. The cells were then subjected to permeabilization by a solution of 200 mL of chloroform and 100 mL of 0.1% SDS prior to the addition of 0.4 mL of o-nitro phenol-b-D-galactopyranoside (4 mg/mL in PBS). Once the yellow colour had developed, 1 mL of 1 M Na 2 CO 3 was supplemented to stop the reaction. The ODs of the reaction samples were measured at 420 and 550 nm. Miller units of b-galactosidase activity were calculated using the formula [(1000×A 420 )-(1.75×A 550 )]/(time×volume×A 600 ). 73, 74 Results are represented as residual activity in percent and the control corresponds to 100%.
Virulence factor assays
Lipase assay A 0.6 mL aliquot of filtered supernatant of bacteria, 0.6 mL of Tween w 20 in Tris-buffered saline (10%), 0.1 mL of CaCl 2 (1 M) and 1.2 mL H 2 O were mixed in a 15 mL tube and incubated at 378C for 24 h with agitation at 200 rpm (Innova 4000 Incubator Shaker; New Brunswick Scientific, NJ, USA). In the presence of lipase, Tween is broken down and bound to calcium, which precipitates and can be measured by turbidity (OD 400 ). 75 Lipase experiments were performed three times in triplicate.
Chitinase assay
The filtered supernatants (1 mL) of bacteria were mixed with 5 mg of insoluble chitin azure and 1 mL of PBS in a 15 mL tube. The mixture was incubated at 378C for 24 h with agitation at 200 rpm (Innova 4000 Incubator Shaker; New Brunswick Scientific, NJ, USA). After centrifugation (16 000 g) to remove insoluble chitin azure, the absorbance was measured at OD 290 . 75 The experiments were repeated three times in triplicate.
Elastase assay
The filtered supernatants (1 mL) were mixed with 20 mg of insoluble elastin-Congo red, and 1 mL of PBS in a 15 mL tube. Elastin-Congo red is insoluble and will sediment at the bottom. The mixture was incubated at 378C for 24 h with agitation on a shaker at 200 rpm (Innova 4000 Incubator Shaker; New Brunswick Scientific, NJ, USA). 76 If elastase is present, it will break down and dissolve elastin, producing a red colour. By centrifugation (16 000 g), the insoluble elastin-Congo red was removed, and the absorbance was read at OD 495 . All of the elastase experiments were perfomed three times in triplicate.
Protease assay
The filtered supernatants (200 mL) obtained from untreated or treated bacteria were added to the wells of Petri dishes (2% agar) containing 3% skimmed milk and incubated for 48 h at 378C. 77 The agar and milk were mixed and 25 mL was poured into each Petri dish and solidified. Holes were made in the agar with the head of a 1 mL pipette tip and 200 mL of the supernatants added carefully into the hole. The dishes were incubated for 24 h at 378C. The zones of clearance (diameter) around the holes were measured directly from the plates with callipers, with three repeats and four replicates, and the experiments were performed three times in triplicate. 76 Antipseudomonal activity of liposomal azithromycin 787 
JAC
Motility studies
The motility studies were performed as described by other investigators.
71
PAO1 grown overnight was diluted to 0.5 McFarland standard (1.5×10 8 cfu/mL), and 1 mL of PAO1 was inoculated onto a 3 mm deep agar plate containing a subinhibitory concentration of free or liposomal azithromycin (1/16 to 1/32 the MIC). Inoculation into the bottom of CAMHB with agarose (1%, w/v) was used for the twitching experiment, and point inoculation onto the medium with agarose (0.3%, w/v) was used for the swimming and swarming experiments (0.5%, w/v). After 24 h of incubation at 378C, swimming and swarming diameters were measured. After 24 h of incubation at 378C, the zone of twitching on the agarose -Petri dish interface was measured by removing the agar and staining the dish surface for 1 min with 1% (w/v) crystal violet. Their diameters were then measured. All of the swimming, swarming and twitching experiments were performed in three separate experiments in triplicate.
Determination of bacterial membrane fusion with liposomes by flow cytometry analysis
Flow cytometry was used to evaluate the fusion of liposomes with bacteria. The liposomes were labelled with PKH2-GL using a PKH2-GL labelling kit (Sigma, St Louis, MO, USA). 78 To study the interactions between biological membranes, a PHK2-GL probe was used in this experiment. In brief, freeze-dried liposomes were rehydrated with PBS and the obtained liposomal pellet was used for the labelling procedure. Labelling was done following the manufacturer's instructions; a 1 mL aliquot was taken and centrifuged for 30 min at 6000 g under 48C. The pellet was then resuspended in 1 mL of diluent A (Sigma, St Louis, MO, USA) and 8 mL of PHK2-GL was added to the pellet. The PHK2-GL liposomal solution was incubated for 5 min at room temperature with circular agitation. Following the incubation, 2 mL of BSA at 1% (w/v) in PBS was added and the solution was further incubated for 1 min with agitation to stop the labelling reaction. Liposomes were then washed twice with PBS by centrifuging at 5000 g for 15 min under 48C to remove any free PKH. Labelling efficiency was determined by flow cytometric analysis.
The incorporation of liposomes into bacterial cells was demonstrated in a fluorescence-activated cell sorting (FACS) analysis using the fluorescent marker PKH2-GL. PAO1 were incubated for 18 h in MH broth and a solution of OD 660 ¼ 0.3 was then prepared. The solution was centrifuged and the bacterial cell pellet was resuspended in RPMI supplemented with 2.5% FCS for washing. The final cell pellet obtained was resuspended in RPMI supplemented with 2.5% FCS to obtain the same initial concentration. Aliquots of 18 mL were then taken and transferred to 50 mL flasks. Bacteria were incubated with 200 mL of liposomes labelled with PHK2-GL, 200 mL of PBS (negative control) and 80 mL of free PKH-2GL (positive control). PBS was then added to the flasks to make the volume up to 20 mL and the flasks were incubated at 378C with agitation (250 rpm). Azithromycin was not encapsulated in liposomes in order to avoid the killing of bacterial cells. Samples of 2 mL were taken after 1, 5 and 10 h of incubation. Liposomes were washed with 2 mL of sucrose cushion of 21% (w/v) in PBS to eliminate free liposomes and the excess PKH2-GL. The obtained bacterial pellet was washed twice with PBS and the final cell pellet was fixed with 300 mL of 2% formaldehyde diluted in PBS for flow cytometry analysis. Samples were analysed in duplicate and data confirmed the slight fusion of liposomes with bacterial cell membranes. The fusion data provided by PKH2-GL fluorescence show the liposomebacterial membrane interactions.
Cytotoxicity test
The cell toxicity studies were done by MTT assay as reported previously. 61 In this study, human lung carcinoma epithelial cell line (A549; ATCC, Manassas, VA, USA) was used for the cell toxicity assay. The lung cells were maintained in DMEM supplemented with 10% FBS. For the MTT assay, the cells were implanted in 96-well plates at a density of 5×10 3 cells/well for subconfluency. The media was eliminated from the wells and replaced with medium containing azithromycin or liposomal azithromycin. The untreated cells containing medium alone were considered as controls. Further, plates were subjected to incubation for 24 h in 5% CO 2 at 378C. After 24 h of exposure, the well was washed once with entire medium and once with Dulbecco's PBS, and replaced with fresh medium. MTT dye was supplemented to each well, the plates were incubated in the dark for 4 h at 378C and MTT lysis buffer was then added to each well of the plate. The well plates were further incubated in the dark overnight at 378C, before taking the measurement at 590 nm spectrophotometrically. Cytotoxicity studies illustrate three separate experiments, performed in triplicate.
Haemolytic test
To further invesitigate the toxicity of liposomal azithromycin, a haemolytic test was performed by erythrocyte haemolysis assay as described in previous studies. 79, 80 The human erythrocytes were pooled and subjected to centrifugation (700 g for 10 min at 48C); they were washed twice by centrifugation (700 g for 10 min at 48C) with 10 times the volume of ice-cold buffer. Later, the washed erythrocytes were re-suspended in 20 times their volume of fresh, ice-cold buffer. In order to perform the haemolysis assay, a 3% erythrocyte solution was prepared by suspending the required quantity of erythrocytes into a haemolysis buffer solution. In a shaking water bath, erythrocytes were incubated under gentle agitation at 378C with empty or azithromycin-containing liposomes for up to 24 h. After incubation, erythrocyte samples were removed and subjected to centrifugation (1000 g for 10 min at 48C). The obtained supernatant was discarded and was centrifuged (15 000 g for 15 min at 48C). In the next step, supernatant was removed and the extent of haemoglobin release was measured spectrophotometrically at 540 nm. The 3% erythrocytes, which represent 0% haemolysis, and red blood cells with 1% Triton X-100, indicating 100% red blood cell lysis, were considered as controls in this study. The haemolysis buffer alone was considered as the blank for measurement. For determining the percentage of haemolysis, a blank of haemolysis buffer was subtracted from all values obtained, estimated using the equation:
Data analysis
The data are presented as means+SEM of three independent experiments. The comparisons of groups were done by one-way analysis of variance (ANOVA) with the Tukey-Kramer Multiple Comparisons Test using InStat 3 from GraphPad prism (GraphPad Software Inc., version 5.0) followed by a post hoc analysis using t-tests. Probability values of *P, 0.05, **P, 0.01 and ***P,0.001 are considered as statistically significant.
Results
Liposomal azithromycin characterizations and stability
The mean particle size of liposomes was 406.07+45 nm and the polydispersity index was 0.3+0.03. The encapsulation efficiency of liposomal azithromycin was 23.8%+0.2% and the concentration of drug entrapped in the liposomes was 0.51+0.004 mg/mL. The DSC curves of pure DPPC, physical mixture-1 (DPPC and cholesterol) and physical mixture-2 (DPPC, cholesterol and azithromycin) are shown in Figure S1 (available as Supplementary data Solleti et al. The stability studies of liposomal azithromycin were performed in PBS at 4 and 378C ( Figure S2 ). The study was performed for a period of 48 h. The liposomal azithromycin stored at 48C was more stable compared with that stored at 378C. Retention of liposomal azithromycin at 48C was 95%, whereas at 378C the retention was 76.3% at the end of the 48 h incubation study period. After 2 h of incubation from the initial period, liposomal azithromycin retention was decreased to 94.6% and 80.3% for 4 and 378C, respectively.
Determination of the MICs and MBCs
The MIC and MBC values of free and liposomal azithromycin for P. aeruginosa are presented Table 1 . The experiments were performed on both mucoid and non-mucoid P. aeruginosa strains.
The MIC values of liposomal azithromycin against both mucoid and non-mucoid P. aeruginosa strains were significantly lower than those of free azithromycin. For example, the MIC value for P. aeruginosa strain PAO1 was 16 mg/L for liposomal azithromycin and 128 mg/L for free azithromycin. The MBC value for PAO1 was 32 mg/L (42.7 mM) for liposomal azithromycin whereas the MBC value of free azithromycin was 256 mg/L (341.8 mM).
Effect of subinhibitory concentrations of free and liposomal azithromycin on the growth of P. aeruginosa
Among all of the subinhibitory concentrations (1/2 to 1/16 the MIC), a value of 1/16 the MIC did not inhibit the growth of bacteria, as shown in Figure 1 . Liposomal azithromycin at 1/2, 1/4 and 1/8 the MIC exhibited a significant reduction in bacterial growth (P, 0.001) compared with control after 2 h of incubation and throughout the study; therefore, liposomal azithromycin and free azithromycin at 1/2, 1/4 and 1/8 the MIC are 
MBEC assay
P. aeruginosa biofilm was exposed to free and liposomal azithromycin at concentrations between 8 and 1024 mg/L (Figure 2 ).
Liposomal and free formulations were able to eradicate bacteria completely at concentrations of 1024 and 512 mg/L. However, liposomal azithromycin formulation at concentrations of 256 -8 mg/L significantly reduced bacterial counts compared with control and free azithromycin (P, 0.001). For example, the liposomal formulation at 8 mg/L more significantly reduced bacterial count compared with 32 mg/L free azithromycin (5.6 log 10 versus 6.3 log 10 ; P,0.001). Furthermore, the liposomal formulation significantly reduced bacterial count at a concentration half that of the free formulation (128 versus 256 mg/L; 3.7 log 10 versus 4.4 log 10 ; P,0.001).
QS molecule reduction
PAO1 strain was exposed to free azithromycin and liposomal azithromycin at 1/16 and 1/32 the MIC (Figure 3 ). The decreased levels of AHL from b-galactosidase activity levels indicated a reduced level of AHL signalling molecules. Liposomal azithromycin reduced QS molecules compared with control and free formulation. For example, liposomal azithromycin at a concentration of 1/16 the MIC exhibited a significant reduction effect on QS compared with 1/16 the MIC of free azithromycin and control (P,0.001). Furthermore, liposomal azithromycin at a concentration of 1/32 the MIC resulted in a significant reduction compared with 1/32 the MIC of free azithromycin and control (P, 0.01). However, liposomal formulation at 1/16 the MIC resulted in significant reduction compared with 1/32 the MIC of free formulation (P,0.001).
Effect of liposomal azithromycin on bacterial virulence factors
Levels of virulence factors (lipase, chitinase, elastase and protease) produced by the P. aeruginosa PAO1 strain when exposed to free and liposomal azithromycin at 1/16 and 1/32 the MIC were examined (Figure 4) . Liposomal azithromycin at 1/32 the MIC had a slight effect on the lipase production compared with the control whereas free azithromycin had no noticeable effect on lipase production (Figure 4a) . Furthermore, the liposomal formulation at 1/16 the MIC reduced the lipase activity significantly compared with the control (P,0.05). For chitinase activity, liposomal azithromycin at 1/32 the MIC reduced the chitinase production compared with the control (Figure 4b ). Furthermore, liposomal formulation reduced the chitinase production significantly at a concentration of 1/16 the MIC compared with the control (P,0.01). For elastase, free azithromycin did not reduce the elastase activity significantly compared with the control, whereas liposomal azithromycin at 1/16 and 1/32 the MIC reduced elastase production significantly compared with the control (P,0.01 and P,0.05, respectively; Figure 4c ). Furthermore, liposomal formulation more significantly reduced elastase activity compared with free formulation at 1/16 and 1/32 the MIC (P,0.05). The protease activity was measured by the halo zones formed in the Petri dishes containing skimmed milk (Figure 4d) . Liposomal azithromycin at a concentration of 1/16 the MIC significantly reduced the protease production compared with the free azithromycin and control (P,0.001). Figure 3 . QS molecule production measured by b-galactosidase activity.
In the presence of free and liposomal azithromycin at 1/16 and 1/32 the MIC, P. aeruginosa PAO1 strain was exposed to free and liposomal azithromycin. Then the supernatants were collected and incubated with the reporter strain A. tumefaciens (A136). Miller units were used to measure the b-galactosidase activities. Each bar represents the mean+SEM of three independent experiments. P values were considered significant when compared with the control and between groups: ***P,0.001 and **P,0.01.
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Effect of liposomal azithromycin on bacterial motility
The P. aeruginosa motility patterns, including twitching, swarming and swimming, were examined in the presence of free and liposomal azithromycin at 1/16 and 1/32 the MIC ( Figure 5 ). For motility, including twitching, swarming and swimming, the liposomal azithromycin at 1/16 the MIC significantly reduced all three motility patterns compared with 1/16 the MIC of free azithromycin (P, 0.001). Similarly, liposomal azithromycin at a concentration of 1/32 the MIC resulted in a significant reduction of different motility patterns compared with 1/32 the MIC of free azithromycin and control (P, 0.001). Significant results for liposomal azithromycin were obtained in all the patterns in comparison with the controls and free azithromycin (P,0.001).
Liposome -bacterial interactions by flow cytometry
Labelled liposomes without antibiotics were utilized to avoid bacterial death due to antibiotics. The fusion of liposomal bilayer PKH2-GL with PAO1 reached 9.9% within 1 h and a maximum of 14.6% after 5 h of contact, showing strengthening of liposome fusion with bacteria. The fusion signal reached 12.3% at 10 h of contact before the fluorescent signals began to decline ( Figure 6 ). A negative panel in the figure indicates the peak of bacterial florescence without label, and positive panels were in the range 50% -65% for the duration of the experiments. The positive panel shows that PKH2-GL was compatible with the bacterial membrane.
Cytotoxicity and haemolytic tests
No cytotoxic effect on A459 cells was observed after incubation with liposomal antibiotic (100%). However, 90% of the cells were viable in the presence of free antibiotic. No significant haemolysis was observed with empty or azithromycin-containing liposomes; the haemolytic activities were ,1%.
Discussion
The present study focused on the preparation of novel liposomal azithromycin formulation by DRV method. 59 An earlier study reported that the preparation of liposomes by DRV method resulted in higher encapsulation efficiency of macrolide antibiotics with greater stability. 58 The particle size and polydispersity index of the liposome formulations are important parameters in characterization of the homogeneity of the liposomes and also for determining long-term stability. 81 In this study, the results obtained for particle size and polydispersity index of liposomal azithromycin formulation were homogenous in nature, indicating long-term stability. 50 Stability studies are another important considerable parameter when developing a novel liposomal formulation. Considering this parameter, we performed stability measurements for liposomal formulations under different environmental conditions (4 and 378C) in PBS for a period of 48 h. The obtained data reveal that the retention of liposomal azithromycin at 48C was 95% and at 378C it was 76.3%, showing that the liposomal azithromycin was The results were normalized by dividing the average absorbance of the virulence factor assays over the OD 600 (bacterial density) at 24 h for lipase, chitinase and elastase experiments. P values were considered significant when compared with the control: ***P, 0.001, **P,0.01 and *P,0.05.
Antipseudomonal activity of liposomal azithromycin 791 JAC more stable at 48C compared with 378C, mainly due to the increase in the acyl chain length of lipid constituents, thereby increasing the stability of formulations containing DPPC at higher transition temperatures. 66 The incorporation of cholesterol during the preparation of liposomes may enhance the stability by reducing the bilayer permeability of the liposomal membrane, which leads to increased drug retention at higher temperatures. 66, 82 After 2 h of incubation in the initial period, liposomal azithromycin retention was . P values were considered significant when compared with the control and between groups: ***P, 0.001 and **P,0.01. Solleti et al.
decreased for both 4 and 378C, possibly due to the structural rearrangement of lipid membranes, and later became consistent. 83 DSC is an analytical technique that is used for characterizing the melting and crystallization properties of crystalline materials. 84 The data obtained from DSC studies show that the slight reduction in the melting transition of liposomal azithromycin when compared with physical mixtures (DPPC, cholesterol and azithromycin) results from the interactions between the lipid material and azithromycin. The intercalated drug molecules might disrupt the hydrogen bonds of liposomes, which leads to changes in the structural arrangement of lipid layers, thereby reducing the melting transition of the azithromycin-loaded liposomes. 67, 85, 86 These DSC profile also provides a molecular understanding of the interaction between a macrolide antibiotic and phospholipids, which could improve understanding of azithromycin -cell interaction. 81 The molecular interaction of azithromycin and DPPC reveals that phase transition of DPPC is strongly decreased due to the increased gap between hydrophobic chains after incorporation of azithromycin into the lipid bilayers. 87, 88 The results from our data demonstrate that the encapsulation of azithromycin into liposomes produces more effective antimicrobial activity against P. aeruginosa than free azithromycin. The MIC and MBC values of liposomal azithromycin were significantly 8-fold lower than those of the free azithromycin. Similar observations were reported by other investigators, showing that the effect of liposome loaded with azithromycin was more bactericidal against P. aeruginosa compared with the free drug due to the increased interaction of the liposomal membrane with the bacterial cell membrane, with the drug being delivered directly in the cytoplasm of the bacteria.
QS is cell-to-cell communication that plays an important role in the formation of biofilms and the production of virulence factors that contribute to resistance to antibiotics. 27, 89, 90 Liposomal azithromycin formulation effectively reduced the production of QS molecules at subinhibitory concentrations. The underlying mechanism involved may be the suppression of las and rhl in the QS system by azithromycin. 91 The liposomal azithromycin reduced QS more significantly that free azithromycin; the reason for this might be increased reduction of chemical signalling molecules by enhanced antibiotic intake into the cell to fuse with the ribosomes, resulting in the down-regulation of QS genes. The use of liposomes as a drug-delivery system may increase the efficacy of drugs and the penetration of drugs into biofilms by longer contact with the bacterial biofilm. 92, 93 The liposomal azithromycin at subinhibitory concentrations reduced the production of virulence factors, including lipase, chitinase, elastase and protease. Earlier studies showed that azithromycin reduced different virulence factors at subinhibitory concentrations 90 by interference with protein synthesis, resulting in the decreased production of virulence factors. 94 Previous studies showed that liposomes promote the consumption of the encapsulated antibiotic, thereby increasing the down-regulation of QS and virulence factor gene expression or reducing the posttranscription synthesis. 74, 92 A similar result demonstrated that clarithromycin-loaded liposome reduced the production of various virulence factors. 59 Many studies have reported that macrolide antibiotics at subinhibitory concentrations inhibit bacterial motility, mainly by interfering with the gene expression and affecting the motility components of the bacteria. 95, 96 We determined the effect of our novel liposomal azithromycin formulation by reducing motility patterns of the bacteria, like twitching, swarming and swimming. This may have occurred due to the improved delivery of the drug into the bacterial cell membranes and cytoplasm, by liposomeloaded drugs, thereby interfering with the motility components of the bacteria such as flagellae and type IV pili. 58, 96 In order to investigate the bacterial cell membrane fusion with liposomes, we performed FACS analysis. The bacterial fusion was assessed by integration of the phospholipid PKH2-GL in bacterial cells. The main characteristic feature of PKH2-GL was used to investigate cell mobility and interactions. 97 The probe facilitated the tracking of liposome interaction with the bacterial cell membrane by FACS analysis. 98 A previous study showed that the integration of PKH2-GL-labelled liposomes with bacterial membranes indicates the direct incorporation of phospholipids into the bacterial cell membranes because the probe inserts its aliphatic carbon tails into membranes; in addition, the dissociation of the probe from the liposomes into the bacterial membrane is due to the strong hydrophobic nature of the probe. 36 The incorporation of PKH2-GL liposomes into bacterial membranes confirms the integration of liposomes with bacterial cell membranes. Similar results were reported earlier by other investigators supporting this study that showed that the enhanced bactericidal effect of liposomal formulation was due to fusion interaction of liposomal membrane with the bacterial cell membrane. 68, 78 The data from the MTT assay show that the liposomal azithromycin has no significant cytotoxic effect on A549 cells. Exposure of A549 human lung cells to liposomal azithromycin reduced the toxicity of the drug. Supporting this hypothesis, earlier research showed that various antibiotic-loaded liposomal formulations reduced toxic effects on A549 human lung cells. 61 For the primary assessment of the phospholipid toxicity of liposomes, blood has been used. 80, 99 In order to investigate the toxicity of liposomal azithromycin, the haemolytic test was performed by erythrocyte haemolysis assay. The data show no haemolytic activity with empty or azithromycin-containing liposomes, suggesting that liposomes are non-toxic to human erythrocytes.
In conclusion, liposomal azithromycin formulation exhibited a significant reduction of P. aeruginosa concentration, bacterial counts within biofilms, QS molecules, virulence factors and motility. Liposomal azithromycin showed no toxicity in vitro and could improve P. aeruginosa infection treatment in CF patients. These data indicate that the liposomal formulation could be a useful therapy to enhance the safety and efficacy of azithromycin against P. aeruginosa lung infection in CF patients.
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